BRIEF

on Telomir Pharmaceuticals, Inc

Telomir Pharmaceuticals Secures $1 Million Equity Funding at Premium

Telomir Pharmaceuticals, Inc., a company pioneering in age-reversal science, announced a $1 million investment from The Starwood Trust. The deal, set at $7 per share, represents a 20% premium to the closing price and includes no warrants. This follows a $5 million non-dilutive credit line secured earlier in the year from the same partner, further solidifying Telomir's financial strategy.

The funding supports Telomir's initiatives towards advancing Telomir-1, their lead compound targeting chronic diseases and aging. Recent preclinical results suggest Telomir-1 may reverse aging effects and tackle Type 2 diabetes at its root cause, showing potential across various age-related conditions.

Erez Aminov, CEO, emphasizes the strength of their financial strategy and the promising preclinical outcomes. Telomir aims to expand research on therapies for conditions ranging from Alzheimer's to cancer, emphasizing a commitment to innovative healthcare solutions.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Telomir Pharmaceuticals, Inc news